BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27523418)

  • 1. [Radiation therapy of pancreatic cancer].
    Huguet F; Mornex F; Orthuon A
    Cancer Radiother; 2016 Sep; 20 Suppl():S169-73. PubMed ID: 27523418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation therapy of pancreatic cancers.
    Huguet F; Rivin Del Campo E; Orthuon A; Mornex F; Bessières I; Guimas V; Vendrely V
    Cancer Radiother; 2022; 26(1-2):259-265. PubMed ID: 34953706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Radiotherapy for primary lung carcinoma].
    Giraud P; Lacornerie T; Mornex F
    Cancer Radiother; 2016 Sep; 20 Suppl():S147-56. PubMed ID: 27516052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radiotherapy of oropharynx carcinoma].
    Servagi Vernat S; Tochet F; Vieillevigne L; Pointreau Y; Maingon P; Giraud P
    Cancer Radiother; 2016 Sep; 20 Suppl():S110-5. PubMed ID: 27521033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Thanikachalam K; Damarla V; Seixas T; Dobrosotskaya I; Wollner I; Kwon D; Winters K; Raoufi M; Li J; Siddiqui F; Khan G
    Am J Clin Oncol; 2020 Jun; 43(6):435-441. PubMed ID: 32251119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radiotherapy in cancers of the oesophagus, the gastric cardia and the stomach].
    Créhange G; Huguet F; Quero L; N'Guyen TV; Mirabel X; Lacornerie T
    Cancer Radiother; 2016 Sep; 20 Suppl():S161-8. PubMed ID: 27523409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer].
    Combs SE; Habermehl D; Werner J; Büchler MW; Debus J
    Chirurg; 2011 Nov; 82(11):981-8. PubMed ID: 22008845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
    Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
    Takahashi H; Ohigashi H; Ishikawa O; Gotoh K; Yamada T; Nagata S; Tomita Y; Eguchi H; Doki Y; Yano M
    Ann Surg; 2012 Jan; 255(1):95-102. PubMed ID: 22123160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
    Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
    Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
    Wang ML; Foo KF
    Singapore Med J; 2009 Jan; 50(1):43-8. PubMed ID: 19224083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
    Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
    PLoS One; 2016; 11(12):e0166606. PubMed ID: 27935952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volumetric modulated arc therapy for advanced pancreatic cancer.
    Eppinga W; Lagerwaard F; Verbakel W; Slotman B; Senan S
    Strahlenther Onkol; 2010 Jul; 186(7):382-7. PubMed ID: 20582394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.